Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_assertion type Assertion NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_head.
- NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_assertion description "[Use of selective COX-2 inhibitors resulted in a significant risk reduction for each type of cancer (71% for breast cancer, 55% for prostate cancer, 70% for colon cancer, and 79% for lung cancer) and an overall 68% risk reduction for all four cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_provenance.
- NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_assertion evidence source_evidence_literature NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_provenance.
- NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_assertion SIO_000772 17612052 NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_provenance.
- NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_assertion wasDerivedFrom befree-2016 NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_provenance.
- NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_assertion wasGeneratedBy ECO_0000203 NP618662.RAdxz-jynPYIp1PxvW0tIman0tvZtmh0XMTpFzCG1j80c130_provenance.